Hepatocellular carcinoma (HCC) is the most common primary liver cancer, the fifth most common cancer in men and the seventh in women, and is associated with high mortality, which is the third leading cause of cancer death. world. This tumor usually develops in patients with underlying chronic liver disease, mainly due to hepatitis B (HBV) and C (HCV) virus infection, alcohol consumption, and non-alcoholic hepatic steatosis. In Spain, alcohol consumption is the most common cause of HCC, followed by HCV infection. In 80% of cases, HCC develops in the context of liver cirrhosis, so the prognosis is determined by tumor extent, liver function and the presence or absence of symptoms. These patients are candidates to receive screening to be able to detect HCC in an initial stage and initiate curative treatment.
Sorafenib; Lenvatinib; Hepatocellular carcinoma; CHC; Neoplasm.
Programa d'Harmonització Farmacoterapèutica. Sorafenib i lenvatinib per al tractament en primera línia del carcinoma hepatocel·lular (CHC). Barcelona: Servei Català de la Salut; 2020.
Use this identifier for quote and/or link this documenthttps://hdl.handle.net/11351/5865
This item appears in following collections
The following license files are associated with this item: